Whalesbook
Marksans Pharma's wholly owned UK subsidiary, Relonchem Limited, has received authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to market Mefenamic Acid Film-Coated Tablets in 250 mg and 500 mg strengths. This approval allows the company to expand its offerings in the UK generics market, targeting short-term relief for mild to moderate pain, including menstrual pain. Marksans Pharma, headquartered in Mumbai, is involved in the research, manufacturing, and global marketing of generic pharmaceutical formulations.
Marksans Pharma Limited, an Indian pharmaceutical company based in Mumbai, has announced a significant development through its wholly owned United Kingdom subsidiary, Relonchem Limited. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for Relonchem Limited to market Mefenamic Acid Film-Coated Tablets in both 250 mg and 500 mg strengths.
Mefenamic Acid is a non-steroidal anti-inflammatory drug (NSAID) used for the short-term relief of mild to moderate pain, particularly effective for conditions such as menstrual pain. This regulatory clearance is a key step for Marksans Pharma as it aims to broaden its product portfolio within the competitive UK generics market.
Following the announcement, Marksans Pharma's shares showed positive movement, opening at ₹194.80 and reaching an intraday high of ₹198.99.
In recent financial results, Marksans Pharma reported a net profit of ₹98.2 crore for the September quarter, a slight increase of 1.5% year-on-year. Revenue saw a healthy growth of 12% to ₹720 crore, driven by consistent demand. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) declined by 1.7% to ₹144.7 crore, with profit margins contracting to 20% from 23%.
The company's UK and Europe operations generated ₹245.3 crore in revenue during the second quarter of FY26. Despite facing pricing pressures in the market, Marksans Pharma managed to meet its revenue and margin targets. The latest MHRA approval, along with new product filings, supports a favorable growth outlook for its UK business.
Impact
This regulatory approval is a positive development for Marksans Pharma, enhancing its product offerings and market presence in the United Kingdom. It could lead to increased sales and revenue contributions from the UK market, further strengthening the company's international footprint. For the broader Indian pharmaceutical sector, this signifies successful navigation of regulatory pathways in developed markets, potentially encouraging other companies.
Rating: 7/10
Difficult Terms:
MHRA: Medicines and Healthcare products Regulatory Agency. This is the UK government agency responsible for regulating medicines and medical devices to ensure they are safe and effective.
Mefenamic Acid: A specific type of non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain, including muscle aches, dental pain, menstrual pain, and headaches.
Film-Coated Tablets: Tablets that have a coating applied to them, which can help mask taste, make them easier to swallow, protect the active ingredients, or control the release of the medication.
Generics Market: The market for generic drugs, which are copies of brand-name drugs that have the same active ingredient, dosage form, strength, and route of administration, but are typically sold at a lower price after the patent on the original drug expires.
EBITDA: Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure of a company's operating performance, indicating profitability before accounting for financing, tax, and non-cash expenses.
Margins: In a business context, margins usually refer to profit margins, which are the percentage of revenue that remains after costs are deducted. This can be gross margin, operating margin, or net margin.
